Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling.

Ganesh T, Min J, Thepchatri P, Du Y, Li L, Lewis I, Wilson L, Fu H, Chiosis G, Dingledine R, Liotta D, Snyder JP, Sun A.

Bioorg Med Chem. 2008 Jul 15;16(14):6903-10. doi: 10.1016/j.bmc.2008.05.047. Epub 2008 May 27.

2.

Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.

Casale E, Amboldi N, Brasca MG, Caronni D, Colombo N, Dalvit C, Felder ER, Fogliatto G, Galvani A, Isacchi A, Polucci P, Riceputi L, Sola F, Visco C, Zuccotto F, Casuscelli F.

Bioorg Med Chem. 2014 Aug 1;22(15):4135-50. doi: 10.1016/j.bmc.2014.05.056. Epub 2014 Jun 14.

PMID:
24980703
3.

Hsp90 inhibitors and drugs from fragment and virtual screening.

Roughley S, Wright L, Brough P, Massey A, Hubbard RE.

Top Curr Chem. 2012;317:61-82. doi: 10.1007/128_2011_181. Review.

PMID:
21647838
4.

Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.

Vallée F, Carrez C, Pilorge F, Dupuy A, Parent A, Bertin L, Thompson F, Ferrari P, Fassy F, Lamberton A, Thomas A, Arrebola R, Guerif S, Rohaut A, Certal V, Ruxer JM, Gouyon T, Delorme C, Jouanen A, Dumas J, Grépin C, Combeau C, Goulaouic H, Dereu N, Mikol V, Mailliet P, Minoux H.

J Med Chem. 2011 Oct 27;54(20):7206-19. doi: 10.1021/jm200784m. Epub 2011 Oct 5. Erratum in: J Med Chem. 2012 Jan 12;55(1):564. Gouyon, Thierry [added].

PMID:
21972823
5.

Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.

Sun HP, Jia JM, Jiang F, Xu XL, Liu F, Guo XK, Cherfaoui B, Huang HZ, Pan Y, You QD.

Eur J Med Chem. 2014 May 22;79:399-412. doi: 10.1016/j.ejmech.2014.03.061. Epub 2014 Mar 21.

PMID:
24763261
6.

Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.

Llauger L, He H, Kim J, Aguirre J, Rosen N, Peters U, Davies P, Chiosis G.

J Med Chem. 2005 Apr 21;48(8):2892-905.

PMID:
15828828
7.

Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.

Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, Ran Y, Mansfield R, Fritz LC, Ulm E, Burrows FJ, Boehm MF.

J Med Chem. 2007 Jun 14;50(12):2767-78. Epub 2007 May 8.

PMID:
17488003
8.

Identification and characterisation of a novel heat shock protein 90 inhibitor ONO4140.

Eachkoti R, Reddy MV, Lieu YK, Cosenza SC, Reddy EP.

Eur J Cancer. 2014 Jul;50(11):1982-92. doi: 10.1016/j.ejca.2014.04.017. Epub 2014 May 15.

PMID:
24835034
9.
10.

Discovery and development of pyrazole-scaffold Hsp90 inhibitors.

McDonald E, Jones K, Brough PA, Drysdale MJ, Workman P.

Curr Top Med Chem. 2006;6(11):1193-203. Review.

PMID:
16842156
11.

Hsp90 molecular chaperone inhibitors: are we there yet?

Neckers L, Workman P.

Clin Cancer Res. 2012 Jan 1;18(1):64-76. doi: 10.1158/1078-0432.CCR-11-1000. Review.

12.

Discovery of 5-substituted 2-amino-4-chloro-8-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7,8-dihydropteridin-6(5H)-ones as potent and selective Hsp90 inhibitors.

Li X, Shocron E, Song A, Patel N, Sun CL.

Bioorg Med Chem Lett. 2009 May 15;19(10):2860-4. doi: 10.1016/j.bmcl.2009.03.074. Epub 2009 Mar 24.

PMID:
19395259
13.

Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.

Sadikot T, Swink M, Eskew JD, Brown D, Zhao H, Kusuma BR, Rajewski RA, Blagg BS, Matts RL, Holzbeierlein JM, Vielhauer GA.

Assay Drug Dev Technol. 2013 Oct;11(8):478-88. doi: 10.1089/adt.2012.498. Epub 2013 Oct 15.

14.

A fluorescence polarization assay for inhibitors of Hsp90.

Howes R, Barril X, Dymock BW, Grant K, Northfield CJ, Robertson AG, Surgenor A, Wayne J, Wright L, James K, Matthews T, Cheung KM, McDonald E, Workman P, Drysdale MJ.

Anal Biochem. 2006 Mar 15;350(2):202-13. Epub 2006 Jan 23.

PMID:
16460658
15.

Improvement of inhibitor identification for heat shock protein 90α by utilizing a red-shifted fluorescence polarization probe.

Qian J, Holskin BP, Theroff J, Underiner T, Meyer SL, Angeles TS.

Assay Drug Dev Technol. 2012 Aug;10(4):375-81. doi: 10.1089/adt.2011.429. Epub 2012 Mar 19.

PMID:
22428803
16.

Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.

Le Brazidec JY, Kamal A, Busch D, Thao L, Zhang L, Timony G, Grecko R, Trent K, Lough R, Salazar T, Khan S, Burrows F, Boehm MF.

J Med Chem. 2004 Jul 15;47(15):3865-73.

PMID:
15239664
17.

Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.

Wright L, Barril X, Dymock B, Sheridan L, Surgenor A, Beswick M, Drysdale M, Collier A, Massey A, Davies N, Fink A, Fromont C, Aherne W, Boxall K, Sharp S, Workman P, Hubbard RE.

Chem Biol. 2004 Jun;11(6):775-85.

18.

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.

Song D, Chaerkady R, Tan AC, García-García E, Nalli A, Suárez-Gauthier A, López-Ríos F, Zhang XF, Solomon A, Tong J, Read M, Fritz C, Jimeno A, Pandey A, Hidalgo M.

Mol Cancer Ther. 2008 Oct;7(10):3275-84. doi: 10.1158/1535-7163.MCT-08-0508.

19.

A compound that inhibits the HOP-Hsp90 complex formation and has unique killing effects in breast cancer cell lines.

Pimienta G, Herbert KM, Regan L.

Mol Pharm. 2011 Dec 5;8(6):2252-61. doi: 10.1021/mp200346y. Epub 2011 Oct 5.

PMID:
21882818
20.

Binding of natural and synthetic inhibitors to human heat shock protein 90 and their clinical application.

Petrikaitė V, Matulis D.

Medicina (Kaunas). 2011;47(8):413-20. Epub 2011 Nov 18. Review.

Supplemental Content

Support Center